US EditionNew ways to treat bladder cancer improve survival and shake up the standard of care, new studies show
- A combination of enfortumab vedotin and pembrolizumab has shown promise in extending overall survival for patients with advanced bladder cancer.
- The new treatment reduced the risk of disease progression or death by 55% compared to standard chemotherapy, and it had a similar safety profile.
- The findings have the potential to change the standard of care for advanced bladder cancer, offering a more effective option for patients.
Insights by Ground AI
Does this summary seem wrong?
34 Articles
34 Articles
All
Left
3
Center
29
Right
1
El cáncer de vejiga avanzado duplica su supervivencia, de 16 meses a casi tres años
Madrid, 24 oct (EFE).- El cáncer de vejiga avanzado se ha convertido en la "estrella" del congreso de la Sociedad Europea de Oncología Médica (ESMO), que se clausura este martes en Madrid, una enfermedad cuyos últimos ensayos, con participación española, duplican la mediana de supervivencia de los pacientes, de 16 meses a casi tres años.Así lo explica en declaraciones a EFE el presidente de la Sociedad Española de Oncología Médica (SEOM), César …
·Buenos Aires, Argentina
Read Full Article
Coverage Details
Total News Sources34
Leaning Left3Leaning Right1Center29Last UpdatedBias Distribution88% Center
Bias Distribution
- 88% of the sources are Center
88% Center
C 88%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
